Genmab A (GMAB) Long-Term Deferred Tax (2023 - 2025)

Genmab A (GMAB) has disclosed Long-Term Deferred Tax for 3 consecutive years, with $171.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Deferred Tax rose 34.65% year-over-year to $171.0 million, compared with a TTM value of $171.0 million through Dec 2025, up 34.65%, and an annual FY2025 reading of $171.0 million, up 34.65% over the prior year.
  • Long-Term Deferred Tax was $171.0 million for Q4 2025 at Genmab A, up from $127.0 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $171.0 million in Q4 2025 and bottomed at $31.0 million in Q4 2023.
  • Average Long-Term Deferred Tax over 3 years is $109.7 million, with a median of $127.0 million recorded in 2024.
  • The sharpest move saw Long-Term Deferred Tax skyrocketed 309.68% in 2024, then skyrocketed 34.65% in 2025.
  • Year by year, Long-Term Deferred Tax stood at $31.0 million in 2023, then surged by 309.68% to $127.0 million in 2024, then surged by 34.65% to $171.0 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for GMAB at $171.0 million in Q4 2025, $127.0 million in Q4 2024, and $31.0 million in Q4 2023.